For example, a routine biomarker screening approach, with NT‐proBNP testing in patients with clinical symptoms suggestive of HF under surgical or anesthesiological care is not yet widely established, although it is recommended in the latest ESC guidelines from 2022 [1]. The gene discussed is NPPB; the disease is hydrops fetalis.